Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)|
- Rate of Adverse Events (Number of Participants Who Experienced Any AE Considered Related to Study Drug) [ Time Frame: 1 year ]
- Number and Causes of Hyperammonemic Events [ Time Frame: 1 year ]Number of hyperammonemic crises per patient
- Blood Ammonia Levels [ Time Frame: 1 Year ]Venous Ammonia levels over time
- Patient Satisfaction With HPN-100 [ Time Frame: Month 1 post dose ]Drug preference will be noted at week 3
|Study Start Date:||November 2009|
|Study Completion Date:||November 2011|
|Primary Completion Date:||September 2011 (Final data collection date for primary outcome measure)|
Patients who were treated with HPN-100
HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
Other Name: GT4P, Glyceryl tri-(4-phenylbutyrate)
This was a one year long-term safety study of HPN-100 in UCD subjects. Subjects were assessed regularly for safety and control of their venous ammonia. Hyperammonemic events were characterized with respect to contributing factors, such as intercurrent illness, diet, and noncompliance with medication.
Forty subjects with a diagnosis of UCD who completed Study HPN-100-006 were enrolled.
Twenty additional UCD subjects ≥ 6 years of age were enrolled. These subjects included those who did not qualify for HPN-100-006 [e.g., subjects between the ages of 6-17; subjects with other UCD subtypes or adult subjects who have not taken sodium phenylbutyrate (NaPBA) in the past 6 months, etc.]. For adult subjects not receiving NaPBA in the past 6 months, subjects must, in the judgment of the investigator, be anticipated to benefit from the addition of a nitrogen-scavenging agent to their current treatment. See the inclusion criteria for examples of clinical evidence of potential benefit.
Monthly assessments included safety laboratory tests, amino acid panel, vital signs, electrocardiogram (ECG) monitoring, venous ammonia, and blood and urine metabolites. Adverse events (AEs) and concomitant medications were recorded on an ongoing basis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00947297
Show 22 Study Locations
|Principal Investigator:||Brendan Lee, MD||Baylor College of Medicine|